Paul Fleming

2.5k total citations
23 papers, 1.4k citations indexed

About

Paul Fleming is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Paul Fleming has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 14 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in Paul Fleming's work include Ubiquitin and proteasome pathways (10 papers), Peptidase Inhibition and Analysis (6 papers) and Cancer Treatment and Pharmacology (4 papers). Paul Fleming is often cited by papers focused on Ubiquitin and proteasome pathways (10 papers), Peptidase Inhibition and Analysis (6 papers) and Cancer Treatment and Pharmacology (4 papers). Paul Fleming collaborates with scholars based in United States, Japan and Norway. Paul Fleming's co-authors include Lawrence R. Dick, Christopher Blackburn, Bing Guan, Kazumi Shiosaki, Paul Hales, Christopher Tsu, Jonathan L. Blank, Khristofer Garcia, Frank J. Bruzzese and Heinz G. Floss and has published in prestigious journals such as Journal of the American Chemical Society, Blood and Cancer Research.

In The Last Decade

Paul Fleming

22 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Fleming United States	12	958	455	395	271	85	23	1.4k
Angelo Aguilar United States	17	1.3k 1.3×	699 1.5×	419 1.1×	195 0.7×	38 0.4×	28	1.8k
Louis Plamondon United States	15	942 1.0×	357 0.8×	429 1.1×	125 0.5×	140 1.6×	27	1.4k
Dale Grabowski United States	22	1.1k 1.1×	650 1.4×	157 0.4×	124 0.5×	50 0.6×	67	1.4k
Radek Jorda Czechia	22	637 0.7×	352 0.8×	541 1.4×	102 0.4×	68 0.8×	75	1.2k
Rooha Contractor United States	14	870 0.9×	469 1.0×	214 0.5×	92 0.3×	31 0.4×	24	1.3k
Anne Marinier Canada	19	686 0.7×	162 0.4×	186 0.5×	299 1.1×	44 0.5×	52	1.1k
Mingfeng Yu Australia	21	674 0.7×	443 1.0×	347 0.9×	88 0.3×	39 0.5×	53	1.3k
Catherine Sylvain France	6	680 0.7×	308 0.7×	221 0.6×	165 0.6×	24 0.3×	11	980
Ningyu Wang China	22	918 1.0×	307 0.7×	338 0.9×	74 0.3×	45 0.5×	84	1.5k
Zanna Beharry United States	21	736 0.8×	279 0.6×	217 0.5×	81 0.3×	58 0.7×	33	1.3k

Countries citing papers authored by Paul Fleming

Since Specialization

Citations

This map shows the geographic impact of Paul Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Fleming more than expected).

Fields of papers citing papers by Paul Fleming

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Fleming. The network helps show where Paul Fleming may publish in the future.

Co-authorship network of co-authors of Paul Fleming

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Fleming. A scholar is included among the top collaborators of Paul Fleming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Fleming. Paul Fleming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Komoike, Yusaku, Yoshiki Nakamura, Takeshi Watanabe, et al.. (2018). MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model. International Immunopharmacology. 60. 160–169. 25 indexed citations

Rahal, Rami, Erica N Evans, Wei Hu, et al.. (2016). Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors. Cancer Research. 76(14_Supplement). 2641–2641. 10 indexed citations

Csizmadia, Vilmos, Paul Hales, Christopher Tsu, et al.. (2016). Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi. Toxicology Research. 5(6). 1619–1628. 10 indexed citations

Milhollen, Michael A., Tary Traore, Jessica J. Huck, et al.. (2015). Abstract A164: The small molecule UAE inhibitor TAK-243 (MLN7243) prevents DNA damage repair and reduces cell viability/tumor growth when combined with radiation, carboplatin and docetaxel. Molecular Cancer Therapeutics. 14(12_Supplement_2). A164–A164. 2 indexed citations

Milhollen, Michael A., Marc L. Hyer, Jeff Ciavarri, et al.. (2014). 561 Nonclinical characterization of the first in class investigational ubiquitin activating enzyme inhibitor MLN7243 in cellular and in vivo models of cancer in support of a phase I study. European Journal of Cancer. 50. 181–182. 1 indexed citations

Blackburn, Christopher, Jonathan L. Blank, Frank J. Bruzzese, et al.. (2012). Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome. MedChemComm. 3(6). 710–719. 9 indexed citations

Bannerman, Bret, Ling Xu, Matthew D. Jones, et al.. (2011). Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemotherapy and Pharmacology. 68(5). 1145–1154. 32 indexed citations

Sappal, Darshan S., Neil Bence, Paul Fleming, et al.. (2011). Cellular and biochemical characterization of an inhibitor of the Ubiquitin Activating Enzyme (UAE). 2. 1 indexed citations

Kupperman, Erik, Edmund C. Lee, Yueying Cao, et al.. (2010). Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer. Cancer Research. 70(5). 1970–1980. 409 indexed citations

10.

Blackburn, Christopher, Jonathan L. Blank, Frank J. Bruzzese, et al.. (2010). Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorganic & Medicinal Chemistry Letters. 20(22). 6581–6586. 39 indexed citations

11.

Dick, Lawrence R. & Paul Fleming. (2010). Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discovery Today. 15(5-6). 243–249. 233 indexed citations

12.

Blackburn, Christopher, Kenneth M. Gigstad, Paul Hales, et al.. (2010). Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit. Biochemical Journal. 430(3). 461–476. 129 indexed citations

13.

Kupperman, Erik, Edmund Lee, Yueying Cao, et al.. (2009). In-Vitro and in-Vivo Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer.. Blood. 114(22). 2709–2709. 1 indexed citations

14.

Doll, Kenneth M., Paul Fleming, & Richard G. Finke. (2002). The synthesis and characterization of 8-methoxy-5′-deoxyadenosylcobalamin: a coenzyme B12 analog which, following Co–C bond homolysis, avoids cyclization of the 8-methoxy-5′-deoxyadenosyl radical. Journal of Inorganic Biochemistry. 91(2). 388–397. 2 indexed citations

15.

Fleming, Paul, Brian E. Daikh, & Richard G. Finke. (1998). The coenzyme B12 derivative N1-methyl-5′-deoxyadenosylcobalamin: Synthesis, characterization, stability towards dimroth rearrangement, and Co–C thermolysis product and kinetic studies. Journal of Inorganic Biochemistry. 69(1-2). 45–57. 12 indexed citations

16.

Blackburn, Christopher, et al.. (1998). ChemInform Abstract: Parallel Synthesis of 3‐Aminoimidazo[1,2‐a]pyridines and ‐pyrazines by a New Three‐Component Condensation.. ChemInform. 29(35). 2 indexed citations

17.

Blackburn, Christopher, et al.. (1998). Parallel synthesis of 3-aminoimidazo[1,2-a]pyridines and pyrazines by a new three-component condensation. Tetrahedron Letters. 39(22). 3635–3638. 304 indexed citations

18.

Fleming, Paul, Heinz G. Floss, Andrew R. Knaggs, et al.. (1994). Biosynthetic studies on taxol. Pure and Applied Chemistry. 66(10-11). 2045–2048. 5 indexed citations

19.

Fleming, Paul, et al.. (1994). Biosynthesis of Taxoids. Mode of Attachment of the Taxol Side Chain. Journal of the American Chemical Society. 116(9). 4137–4138. 28 indexed citations

20.

Alelyunas, Yun W., et al.. (1991). Rare .alpha.-alkyl isomers of cobalamins: synthesis, characterization, and properties of two diastereomers of the .alpha.-alkylcobalamin, .alpha.-(2-oxo-1,3-dioxolan-4-yl)cobalamin. Journal of the American Chemical Society. 113(10). 3781–3794. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact